Arrowhead (NASDAQ: ARWR) director logs planned common stock sales

Rhea-AI Filing Summary

Arrowhead Pharmaceuticals director reports planned stock sales under a Rule 10b5-1 trading plan. On 12/19/2025, the reporting person sold three blocks of Arrowhead common stock: 3,090 shares at a weighted average price of $66.7, 6,083 shares at a weighted average price of $68.04, and 827 shares at a weighted average price of $68.48.

The filing states these sales were made under a pre‑established 10b5-1 trading plan adopted in accordance with securities regulations. After these transactions, the reporting person beneficially owns 33,600 shares of Arrowhead common stock, which includes shares underlying restricted stock units that remain subject to vesting conditions.

Insider Trade Summary

Net Seller: 10,000 shares ($676,623)

Net Sell 3 txns

Insider OLUKOTUN ADEOYE Y

Role Director

Sold 10,000 shs ($677K)

Type	Security	Shares	Price	Value
Sale	Common Stock	3,090	$66.70	$206K
Sale	Common Stock	6,083	$68.04	$414K
Sale	Common Stock	827	$68.48	$57K

Holdings After Transaction: Common Stock — 40,510 shares (Direct)

Footnotes (1)

1. Shares were sold pursuant to a 10b5-1 trading plan adopted by the Reporting Person in accordance with Rule 10b5-1 of the Securities Exchange Act of 1934, as amended. The price reported on Column 4 is the weighted average price. These shares were sold in multiple transactions at prices ranging from $66.52 to $67.40, inclusive. The reporting person undertakes to provide to Arrowhead Pharmaceuticals, Inc., any security holder of Arrowhead Pharmaceuticals, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote of this Form 4. Includes previously reported shares of common stock underlying Restricted Stock Units granted to the Reporting person, a portion of which are still subject to certain vesting conditions. The price reported on Column 4 is the weighted average price. These shares were sold in multiple transactions at prices ranging from $67.62 to $68.30, inclusive. The reporting person undertakes to provide to Arrowhead Pharmaceuticals, Inc., any security holder of Arrowhead Pharmaceuticals, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote of this Form 4. The price reported on Column 4 is the weighted average price. These shares were sold in multiple transactions at prices ranging from $68.38 to $68.56, inclusive. The reporting person undertakes to provide to Arrowhead Pharmaceuticals, Inc., any security holder of Arrowhead Pharmaceuticals, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote of this Form 4.

Form 4 Insider Transactions: What Each Field Means →

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

X

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

OLUKOTUN ADEOYE Y

(Last) (First) (Middle)

177 E COLORADO BLVD

STE 700

(Street)

PASADENA CA 91105

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
ARROWHEAD PHARMACEUTICALS, INC. [ ARWR ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

3. Date of Earliest Transaction (Month/Day/Year)
12/19/2025

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	12/19/2025		S		3,090(1)	D	$66.7(2)	40,510(3)	D
Common Stock	12/19/2025		S		6,083(1)	D	$68.04(4)	34,427(3)	D
Common Stock	12/19/2025		S		827(1)	D	$68.48(5)	33,600(3)	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. Shares were sold pursuant to a 10b5-1 trading plan adopted by the Reporting Person in accordance with Rule 10b5-1 of the Securities Exchange Act of 1934, as amended.

2. The price reported on Column 4 is the weighted average price. These shares were sold in multiple transactions at prices ranging from $66.52 to $67.40, inclusive. The reporting person undertakes to provide to Arrowhead Pharmaceuticals, Inc., any security holder of Arrowhead Pharmaceuticals, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote of this Form 4.

3. Includes previously reported shares of common stock underlying Restricted Stock Units granted to the Reporting person, a portion of which are still subject to certain vesting conditions.

4. The price reported on Column 4 is the weighted average price. These shares were sold in multiple transactions at prices ranging from $67.62 to $68.30, inclusive. The reporting person undertakes to provide to Arrowhead Pharmaceuticals, Inc., any security holder of Arrowhead Pharmaceuticals, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote of this Form 4.

5. The price reported on Column 4 is the weighted average price. These shares were sold in multiple transactions at prices ranging from $68.38 to $68.56, inclusive. The reporting person undertakes to provide to Arrowhead Pharmaceuticals, Inc., any security holder of Arrowhead Pharmaceuticals, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote of this Form 4.

Remarks:

	/s/Adeoye Olukotun	12/23/2025
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What insider transaction did Arrowhead Pharmaceuticals (ARWR) disclose?

The filing reports that a director of Arrowhead Pharmaceuticals, Inc. sold shares of the company’s common stock on 12/19/2025, disclosed on a Form 4.

How many Arrowhead (ARWR) shares did the director sell and at what prices?

The director sold 3,090 shares at a weighted average price of $66.7, 6,083 shares at a weighted average price of $68.04, and 827 shares at a weighted average price of $68.48.

Were the ARWR insider stock sales part of a 10b5-1 trading plan?

Yes. The filing explains that the shares were sold pursuant to a Rule 10b5-1 trading plan adopted by the reporting person in accordance with the Securities Exchange Act of 1934.

What price ranges were involved in the Arrowhead (ARWR) stock sales?

The weighted average prices reflect multiple trades: from $66.52 to $67.40 for one group of sales, $67.62 to $68.30 for another, and $68.38 to $68.56 for the final group.

How many Arrowhead Pharmaceuticals shares does the director own after these sales?

After the reported transactions, the director beneficially owns 33,600 shares of Arrowhead common stock, including shares underlying restricted stock units that are still subject to vesting.

What is the reporting person’s relationship to Arrowhead Pharmaceuticals (ARWR)?

The reporting person is identified as a director of Arrowhead Pharmaceuticals, Inc., and the Form 4 is filed as a Form filed by One Reporting Person.